Key result
4F-PCC was noninferior to plasma for 24-hour hemostatic efficacy (72.4% vs 65.4%; difference 7.1%, 95% CI -5.8 to 19.9) and superior for rapid INR reduction (62.2% vs 9.6%).
Why the study?
Does 4F-PCC improve hemostatic efficacy and INR correction compared to plasma in patients on vitamin K antagonists presenting with major bleeding?
Population
202 nonsurgical patients experiencing major bleeding while taking vitamin K antagonists requiring rapid…
Comparison
Nonactivated 4-factor prothrombin complex… vs Plasma
Design
RCT, randomized, open-label
Follow-up
24 hours
Authors
Loading...
Observational data support 4F-PCC for faster INR reversal; randomized trials needed to confirm hemostatic efficacy.
RCT (n=202)
open-label
randomized
Yes
Does 4F-PCC improve hemostatic efficacy and INR correction compared to plasma in patients on vitamin K antagonists presenting with major bleeding?
Effect estimate: difference 7.1% (95% CI -5.8 to 19.9)
Absolute Event Rate: 72.4% vs 65.4%
4F-PCC is an effective alternative to plasma for urgent reversal of vitamin K antagonist therapy in major bleeding events, demonstrating noninferior hemostatic efficacy and superior rapid INR reduction.
Sarode et al. (2013) conducted an RCT in Major bleeding while taking vitamin K antagonists (n=202). 4-factor prothrombin complex concentrate (4F-PCC) vs. plasma was evaluated on 24-hour hemostatic efficacy from start of infusion and international normalized ratio correction (≤1.3) at 0.5 hour after end of infusion (difference 7.1%, 95% CI -5.8 to 19.9). 4F-PCC was noninferior to plasma for 24-hour hemostatic efficacy (72.4% vs 65.4%; difference 7.1%, 95% CI -5.8 to 19.9) and superior for rapid INR reduction (62.2% vs 9.6%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: